Introduction
The regeneration or replacement o unctional tissues after heart damage has been traditionally considered a 'mission impossible' in cardiology. Reperfusion of the ischaemic myocardium was the only intervention available to restore the various cellular functions a ected by myocardial ischaemia. Recently myocardium self repair by regeneration from autologous and undi erentiated primitive cells or di erentiated cells with proliferative properties has been theorized [1] . However, this reparative process has demonstrated limited clinical importance due to the poor capacity of regeneration and proliferation of autologous human cardiomyocytes to prevent either the scar formation that follows myocardial infarction and the loss of heart function occurring in patients with cardiomyopathy and heart failure.
Recent hopes have risen from experiences that demonstrated the possibility of replacement and regeneration o unctional cardiac muscle achieved either by stem cells.
The term 'stem cell' arose from the concept that these cells have properties analogous to those of the stem of a plant. In plants, the stem may grow to produce more stem, that is, more o t, or di erent structures such as leaves or owers. This elegantly illustrates the two key properties that de ne stem cells. Firstly, they have the ability to renew themselves for long periods through cell division. Secondly, under speci c conditions they can di erentiat e into a spectrum of di erent cell types.
Stem cells have a hierarchy in terms of their ability to di erentiate into other cell types. This ability is termed their di erentiation 'potential'. In nature, the stem cell with the greatest ability to di erentiate into various di erent cell types is the zygote, which is termed 'totipotent' as all cell types of the body arise from it. An embryonic stem cell, which arises from subsequent division of a zygote, is termed 'pluripotent' as it is capable of di erentiating into any cell type from any of the three germ layers (i.e., endoderm, mesoderm, ectoderm). Adult stem cells, which are present in all adult mammals, are termed 'multipotent' given their ability to di erentiate into di erent tissue types. Finally, the committed progenitor cell is termed 'unipotent' as it is destined only to become one cell type.
Broadly, stem cells can be initially classi ed into embryonic or nonembryonic with the nonembryonic category being subsequently split into adult stem cells and cord blood stem cells. One of the central and recurring questions of all stem cell treatment modalities is which type of stem cells to use in which setting?
For heart regeneration di erent approaches have been proposed, such as the transplantation of allogenic cells (e.g. embryonic stem cells, bone marrow mesenchymal cells or skeletal myoblast) or by stimulation of autologous stem cells and/or resident progenitor cells.
Embryonic stem cells
The most primitive of all stem cells are the embryonic stem cells that develop as the inner cell mass in the Original article human blastocyst at day 5 after fertilization: embryonic stem cells have vast developmental potential as they can give rise to cells of the three embryonic germ layers. They can undergo cell proliferation and form embryolike aggregates (termed embryoid bodies) in vitro, some of which can spontaneously contract. The beating embryoid bodies contain a mixed population of newly di erentiated cell types including cardiomyocytes. Embryonic stem cells spontaneously di erentiate into endothelial progenitor cells (EPC), haemangioblasts, mesenchymal stem cells (MSC). Haemangioblasts further di erentiate generating both haematopoietic stem cells (HSC) and EPC, which give rise to both vascular blood and myocyte components. Under the appropriate conditions (most of which remain to be determined), cardiomyocytes can form from embryoid bodies as well as from EPC and MSC (Fig. 1) .
Embryonic stem cells have raised particular interest, since as the prototypical stem cell, they unequivocally ful ll all of the criteria of stemness: clonality, selfrenewal, and multipotency [2, 3] . Embryonic stem cells can di erentiate into all cell types required in the adult and hold the potential to completely regenerate the myocardium. Ethical issues that ensued from human embryonic stem cell derivation requiring the destruction of human embryos, technical hurdles with maintaining survival of transplanted cells, and the concerns of immunologic rejection and teratoma formation stand as obstacles in the path of embryonic stem cell-based therapy [4] . However, these limitations may be overcome with advances in our understanding of the speci cation and di erentiation of embryonic stem cell-derived cardiomyocytes, alongside methods to limit tumourigenesis, including genetic preprogramming or in-vitro di erentiation before injection. One alternative was proposed by Takahashi and Yamanaka: [5] in mouse embryonic or adult broblast cultures could generate pluripotent stemcell-like cells (induced pluripotent stem (iPS) cells), showing the essential characteristics of embryonic stem cells in terms of morphology, cell-surface markers, geneexpression pro les and telomerase activity. Furthermore, iPS cell clones could be maintained in culture for several months at least and could be induced to di erentiate into derivatives of all three embryonic germ layers both in vitro and in vivo. These studies open up exciting prospects. However, the present methods for generating iPS cells require genetic integration by retroviruses or lentiviruses: [6] ongoing work focuses on in uencing cardiomyocyte speci cation from embryonic stem cells by manipulating signalling to enable the therapeutic strategy of preselecting committed embryonic stem derived cardiac progenitors for transplantation [7] . In conclusion embryonic stem cells cannot be considered a viable option for cellular cardiomyoplasty until the several open issue have not been successfully solved.
Although di erent types of cells have been studied, in clinical settings adult skeletal myoblast cells and bone marrow stem cells have been more extensively evaluated, together with stimulation of stem and progenitor cells because their use bypasses much of the ethical and legal issues raised by the use of embryonic stem cells.
Adult skeletal myoblast cells
The rst clinical studies of myocardial regeneration were performed using adult skeletal myoblast cells. When transplanted, these stem cells can successfully home and engraft within a damaged myocardium, preventing progressive ventricular dilatation and improving cardiac function [8, 9] . The myoblasts can be delivered into the myocardium by either intramural implantation or arterial delivery [10, 11] . Skeletal muscle satellite cells can proliferate abundantly in culture; and can be easily grown from the patients themselves (autologous) thereby, avoiding potential immune response. Myoblasts are relatively ischaemia-resistant (compared with cardiomyocytes which become injured within 20 min) and they can withstand several hours of severe ischaemia without becoming irreversibly injured [12] . In animal model of dilated cardiomyopathy the use of skeletal myoblasts, delivered by multiple intramyocardial injections, was e ective in restoring left ventricular function, demonstrating that the functional bene ts of transplanted skeletal myoblast can be extended to nonischaemic cardiomyopathy [13] .
Human studies
After an initial case report [14] , few small, nonrandomized trials investigating the safety and feasibility of Embryonic stem cells spontaneously di erentiate into endothelial progenitor cells, haemangioblasts, mesenchymal stem cells and embryoid bodies. Haemangioblasts further di erentiate generating both haematopoietic stem cells (HSC) and EPC, which give rise to both vascular blood and myocyte components.
myoblast transplantation in patients with ischaemia cardiomyopathy have been published which have shown the ef cacy of autologous skeletal myoblast transplantation in patients with left ventricular (LV) dysfunction [9] . In contrast more recently a large randomized controlled trial failed in showing any signi cant bene cial e ects in global or regional LV function (Table 1 ) [15] [16] [17] [18] [19] [20] [21] [22] [23] .
Thus, several aspects warrant further investigation. The transdi erentiation to a cardiomyocyte-phenotype has not been unequivocally demonstrated [24] . Grafted myoblasts may display incompatible 'wiring' or cell-to-cell connections with resident cardiomyocytes and do not respond in the same way to electrical signalling and stimuli [25] . More importantly, patients receiving skeletal myoblast transplant have experienced severe and often life-threatening arrhythmias. In a rst clinical trial, four out of 10 patients with severely reduced LVEF undergoing CABG after myoblast injections into scar tissue developed sustained ventricular tachycardias both acutely and several months after the operation [15] . In the larger MAGIC trial an increased risk of ventricular arrhythmias occurring in the transplanted patients was recently con rmed [23] . In the absence of electromechanical coupling, the underlying mechanisms remain uncertain. It has been proposed that the ability of myoblasts to re bursts of action potentials may induce deleterious extrasystoles, through electrotonic interaction. On the contrary, the arrhythmias may be promoted by the medium used to introduce the cells, rather than by the cells themselves [19] . Parenthetically, the functional bene ts of myoblast transplantation may be related to the limitation of adverse postinfarction remodelling and/or the paracrine e ects of transplanted myoblasts on recipient tissue, rather than to a grafted-myoblast contribution to enhance ventricular systolic function.
On the basis of these limitations, no rm conclusions regarding ef cacy can be drawn at this time.
Bone-marrow stem cells
Interest in bone marrow derived stem cells (BMC) has been mainly motivated by their potential to di erentiate in cardiomyocytes, or endothelial cells and these properties are enhanced by speci c growth factors and cytokines.
Experimental studies
The bene cial e ects of BMC were shown on myocardial damage in mice [26] in which implanted BMC could di erentiate into myocytes and coronary vessels and thereby ameliorate the function of the injured heart. Similar ndings of cell-mediated repair of myocardial infarction were reproduced in mouse model [27] .
Bone marrow contains several stem cell populations with overlapping phenotypes, including endothelial Cardiac regeneration Piepoli 3 Table 1 Clinical studies using skeletal myoblasts-based cell therapy in humans (with chronic ischaemic heart failure) stem/precursor cells (EPCs), haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and multipotent adult progenitor cells (MAPCs) [28] . In experimental setting adult EPCs transdi erentiate into active cardiomyocytes [29] , although how extensively this occurs in clinical setting is presently unknown. Although this cell-mediated myocardial repair was initially characterized as resulting from HSC's ability to transdi erentiate to cardiomyocytes, HSC plasticity has been dif cult to reproduce and both its signi cance and basis remain undetermined.
Bone marrow-derived MSC and stromal cells (thought to have many properties of MSC) exhibit a high degree of plasticity allowing them to be employed as a selfrenewing autologous source of progenitor cells (from adults), with the potential for di erentiating into cardiomyocytes and can be used in cellular cardiomyoplasty in vitro and in vivo by creating three-dimensional aggregates upto 50% of human MSC express cardiac protein [30] .
Upon treatment with speci c agents (e.g. 5-azacytidine), MSCs can di erentiate into synchronously beating cardiomyocytes [31] . The injection of MSCs after their expansion in culture can also be used in the rescue of an abnormal mouse cardiac phenotype [32] and may prove e ective in repairing a broader array of cardiac damage including myocardial infarct. Furthermore, these bonemarrow derived stem/precursor cells also can prevent the progression of cardiomyocyte apoptosis and stem cardiac remodelling [33] . However, an experimental study using MSC subpopulation reported the appearance of microinfarctions following intracoronary delivery to a canine heart and suggested that care must be exercised when puri ed BMC subpopulation are studied [34] .
Furthermore the mechanism of BMC-mediated augmentation of cardiomyocyte number and function remains controversial: transdi erentiation [28] , cell fusion with preexisting cardiomyocytes, paracrine e ects of transfected cells have been hypothesized [35] Cell fusion has been demonstrated between cardiomyocytes and noncardiomyocytes in vivo and in vitro [36] whereas the data in support of transdi erentiation (particularly with HSCs) have not always been replicable. Further research is needed to clarify these issues.
Human studies in acute myocardial infarction
Inspired by the exciting experimental data, several trials were initiated to test whether cell therapy is well tolerated and feasible in patients after acute myocardial infarction (AMI). Some have decried the clinical trials as being premature without a more complete understanding of the underlying mechanisms [37] , whereas others have pointed out that the clinical trials are justi ed by the potential bene ts of cell therapy [38] All clinical studies included patients with AMI who had undergone primary angioplasty and stent implantation to reopen the infarctrelated artery, and cells were infused intracoronary by using the stop-ow balloon catheter approach. In this regard, the clinical studies di er signi cantly from the animal studies, where the infarct related artery was not reperfused and cells were directly injected into the myocardium. The clinical trials using BMC are presented in Table 2 [22, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] : the combined experience from several hundreds of patients suggests that intracoronary delivery of unselected BMCs (all nucleated cells or mononuclear cell fraction only) is well tolerated in the short-term and mid-term (3-18 months). Furthermore in the larger study, the REPAIR-AMI trial, intracoronary infusion of BMC was associated with a reduction in the prespeci ed combined clinical end point of death, recurrence of myocardial infarction, and any revascularization procedure at 1 year [49] .
This trial has also shown that the patients with a baseline LVEF at or below the median value derived the most bene t. The magnitude of LV contractile recovery was inversely related to the baseline LVEF, con rming similar observations in the Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) pilot trial [41] . Thus, enhanced recovery of contractile function may be bene cial speci cally in patients with large infarcts and depressed LV function. Interesting a dose-related e ect of autologous BMC transplantation on the myocardial function has been con rmed by a recent meta-analysis [52] .
Clinical surveillance, Holter monitoring, and data from an electrophysiological study indicate that intracoronary BMC transfer is not associated with an increased propensity to ventricular (or supraventricular) arrhythmias. Direct injection of ltered nucleated BMCs into the acutely infarcted myocardium in rats has been found to induce intramyocardial calci cations. No evidence for intramyocardial calci cations (or tumour formation) has been obtained in patients in the longer follow-up study after intracoronary delivery of Ficoll or gelatin gradientpuri ed BMCs [47] .
No bleeding complications were noted after bone marrow harvest. Intracoronary BMC infusions did not appear to in ict additional ischaemia damage to the myocardium or to promote a systemic in ammatory reaction, because no further increases in serum troponin or CRP levels were observed. No increased rates o n-stent restenosis were observed after transfer of unselected BMCs, but only after selected CD133 þ population were used [45] . More evidences are necessary to establish that these side e ects are causally related to a speci c subpopulation cell transfer.
So far no trial has demonstrated a signi cant e ect of unselected BMC transfer on LV end-diastolic volumes, suggesting a limited impact on LV remodelling after AMI. Only MSC transplantation has shown improvement in regional wall motion and global LVEF and reduction in LV end-diastolic volume compared with a randomized control group that had received an intracoronary infusion of physiological saline, although a clear description of the cellular preparation is lacking in this report [44] .
Autologous and allogeneic MSCs have been used in several clinical trials including Crohn disease, osteogenesis imperfecta, and graft-versus-host disease. A multicentre, phase I, placebo-controlled, double-blind trial of allogeneic MSCs has been completed and will provide information regarding the safety and ef cacy o ntravenously administered cells in patients with acute myocardial infarction (MI).
Stem cell selection and preparation prior to delivery to increase the density of the cell type o nterest at the site of transplantation have been investigated not only to augment the rate of success in tissue regeneration but also to minimize the chance of cotransplanting contaminating undi erentiated stem cells and hence reduce the risk of developing a teratoma. Cell sorting using cell typespeci c membrane markers, genetic methods using celltype-speci c promoter or selected survival by antibiotic resistance have been proposed [53] .
Human studies in chronic cardiomyopathy
Few trials studies have investigated the application of stem cells in chronic cardiomyopathy mainly with left ventricular dysfunction: all but one [54] of these studies was performed in chronic ischaemic heart diseases (Table 3 ) [22, [54] [55] [56] [57] [58] [59] [60] [61] . The rst trials were uncontrolled: no procedure-related complications nor serious ventricular arrhythmias were observed upto 14 months but perfusion of the cell-injected area and LVEF were improved. However, because of the lack of a control group, the ef cacy of this approach was uncertain. More recently two trials were randomized controlled have been published, both performed in ischaemic cardiomyopathy but with disappointed results: in one intracoronary infusions of unselected mononuclear BMCs by the stop-ow balloon catheter technique had a limited e ect on LVEF [59] , whereas in the other where BMCs were infused either intracoronary or transendocardially no e ect was reported [22] .
Probably the infusion in chronic necrotic or underperfused areas, does not favour the growth and proliferation of BMCs, determining the inef cacy of this technique for myocardial generation.
Stem cells and progenitor cell stimulation
As implantation of BMCs initially required surgical intervention and the procedure was often accompanied by a high mortality rate, with only a 40% of successful grafting, Cardiac regeneration Piepoli 5 Table 2 Clinical studies using autologous bone marrow cells in AMI 
After thrombolytic therapy the development of noninvasive method became imperative. One such approach employed cytokine treatment, stem cell factor (SCF) and/or granulocyte colony-stimulating factor (GCSF) to mobilize endogenous BMCs and direct their integration or homing to the infarcted heart promoting repair.
Experimental studies
The rst suggestion that cytokine-induced stem cell mobilization may be used to enhance cardiac repair came from studies to increase EPC levels for neovascularization in hind limb ischaemia. Mice injected with SCF and GCSF exhibited a substantial increase in the number of circulating stem cells (from 29 in nontreated controls to 7200 in cytokine-treated mice). This approach demonstrated to stimulate myogenesis and angiogenesis in the infarcted area and to improve cardiac function after AMI [62, 63] . It has been postulated that GCSF may accelerate infarct healing by enhancing macrophage in ltration and matrix metalloproteinase activation, and suppress cardiomyocyte apoptosis by activating the cytoprotective STAT3 transcription factor, suggesting that stem cellindependent mechanisms may contribute to the e ects of GCSF after AMI.
Human studies
Animal studies rapidly led to initiation of clinical trials to assess the ability of G-CSF to mobilize stem/progenitor cells in patients with coronary artery disease [64] and AMI [65] . G-CSF-mobilized blood from patients contained 5-fold to 100-fold higher levels of HSCs, MSCs, and EPCs, compared with nonmobilized blood; however, the ability of these cells to improve cardiac remodelling and function after AMI has been disappointing [66] . Some initial concerns regarding the safety of this approach few days after AMI was raised in clinical settings (Table 4) [67] [68] [69] [70] [71] [72] [73] . In a rst clinical investigation [67] , no deaths or substantial arrhythmias, aggravation of heart failure, or angina occurred during GCSF administration and a 6-month follow-up period, but infusions of GCSF mobilized peripheral blood-derived leukocytes and induced a 65% increase in serum creatine kinase-MB levels, indicative of mild myocardial damage. More seriously, 7 out of ten treated patients developed in-stent restenosis at 6 months, which prompted a premature termination of the study. GCSF has the potential to activate neutrophils, by stimulating adhesion to endothelial cells thereby in uencing their recruitment at sites o n ammation and tissue injury. It was hypothesized that these systemic e ects of G-CSF may have contributed to excess neointima proliferation and restenosis.
Less worrisome results came from the FIRSTLINE-AMI study [68] , and the REVIVAL [69] trial where GCSF treatment after stent implantation was not associated with an enhanced rate o n-stent restenosis, or other serious adverse events: but only the FIRSTLINE-AMI Table 3 Clinical Studies Using stem cells in chronic cardiomyopathy 
study showed some positive ndings, where the bene cial e ects of GCSF were magni ed by an unexpected decrease in LVEF in the control group. A slightly di erent and complementary approach has been proposed to amplify stem cell mobilization, with positive results and no complication: after being harvested by daily G-CSF injection for 3-5 days BMC were isolated by apheresis and delivered via an over-the-wire balloon catheter.
Open issues and future developments
What is the mechanism of action? Large debates have been promoted by the lack of any clear information on the exact mechanisms responsible for the observed bene t of this regenerative therapy. It seems that the weight of the evidence implicates mechanisms other than cellular dedi erentiation and di usion. Di erent cell types, derived from tissues as varied as cord blood, adipose tissue and peripheral blood, behave similarly to bone-marrow cells after being injected directly into the heart or travelling to the ischaemic site after intravenous injection, and therefore any reported improvements in cardiac function are likely to be mediated predominantly by paracrine e ects [74] .
What is the best stem cell delivery route? Multiple method of delivery for stem cells have been investigated but the optimal route is still obscure. The optimal delivery route for autologous cell transplantation not only varies according to the administered cell type but will be in uenced in the future by our ability to enhance the migratory capacity of stem cells.
Systemic delivery of stem cells can be an easy method for the regeneration of the injured heart but its e ectiveness is dependent on successful homing and retention of cells before the secretion of paracrine factors or transdi erentiation, or both. Alternatively, for a direct delivery to the heart, two ways have been experimented: either by an intracoronary arterial route or by injection into the ventricular wall via percutaneous endocardial, percutaneous transcoronary venous, or surgical epicardial approaches. Intracoronary delivery enables the application of a maximum dose of cells homogeneously to the site o njury although this mode is less ef cient for delivery to nonperfused regions of the infarct related artery. Homing of intraarterially applied progenitor cells requires their extravasation and migration to the surrounding ischaemia tissue. Although BMCs and haematopoietic stem cells can extravasate [75] , this has not been shown for all cell types and larger, less motile cells, such as skeletal myoblasts may even obstruct the microcirculation, leading to embolic MI [76] . Direct injection is the preferred delivery method for chronic heart failure patients with considerable scar tissue. Cell homing signals such as SDF-1 and VEGF are expressed at low levels at late stages of Cardiac regeneration Piepoli 7 Table 4 Clinical studies using stem and progenitor cell mobilization Table 1 .
disease, limiting any homing potential following intracoronary application [77] .
Injection into the injured myocardium is particularly suited for large cells such as myoblasts and mesenchymal stem cells and is not limited by cell uptake from the circulation or embolic risk. However, injection of progenitor cells into necrotic tissue, which lacks both blood ow to provide oxygen and nutrients and healthy surrounding cardiomyocytes to provide paracrine support, reduces graft survival and di erentiation.
Is there any role for the cardiac resident stem cells? Encouraging new perspectives have been harvested by the possibility to promote cardiac resident stem cells. The rst indication that the adult heart harboured a population of stem cells possessing regenerative properties came from a study of AMI patients showing an elevated number o mmature cardiomyocytes, capable of mitotic division, in the infarct border zone [78] . Whether these progenitors were of endogenous or circulating origin was uncertain, but the identi cation of a resident stem cell population within the heart, which supports myocardial regeneration, has exposed new opportunities for cardiac repair [79] .
A word of cautious has been raised, however. Over the past few years, cell populations expressing stem-cell marker proteins such as Kit, stem-cell antigen 1 (SCA1) and multidrug resistance protein 1 (MDR1) have been identi ed in the human or mouse heart, or both, albeit in minuscule quantities [80] . Although the initial evidence for an adult stem cell or progenitor-cell population in the adult heart, which could potentially be harnessed for cardiac repair, was initially welcomed with enthusiasm, scepticism has since grown. These Kitexpressing cells in tissues of solid organs, including the heart, are thought to have left the bone marrow in minuscule quantities to scavenge pathogenic molecules in peripheral tissues as part of a mechanism to promote a local innate immune response. They are not then actual heart cells but bone-marrow cells out of place. In addition, many of the cells expressing Kit that were detected in biopsied samples of adult human heart were recently reported to coexpress markers of mast cells (cells of the immune system) and to lack expression of cardiac transcription factors NKX2-5 and islet 1 (Isl1), crucial markers of the cardiac progenitor cell state in fetal hearts [81] . These cells are, therefore, not cardiac progenitor cells at all.
Two approaches are currently under investigation to further investigate this issue. The rst is to explant cardiac stem cells from the heart, induce their proliferation and di erentiation ex vivoand to engraft them back into the damaged heart [82] ; and the second, which to date has received less attention, is to stimulate cardiac progenitor cells in situ to proliferate, migrate, and di erentiate in the infarcted heart without ex-vivo manipulation.
Among the rst approach, a clinically applicable method for the isolation and expansion of adult human cardiac stem cells from percutaneous endomyocardial biopsy specimens has been recently proposed. In culture, human cardiac stem cells self-organize into spherical clusters called cardiospheres. Human and porcine cardiospheres can di erentiate into cardiac myocytes in vitro. For in-vivo experiments, infarcts in mice with severe combined immunode ciency were created: direct injection of human cardiospheres into the infarct border zone led to myocardial regeneration by histology and to functional improvement [83] .
For the second approach, a major therapeutic goal is the identi cation o actors that stimulate cardiac stem cells to form replacement cardiomyocytes and vascular progenitors for regeneration of the injured heart [84] .
Other open issues?
The di erent results in di erent clinical trials (e.g. STEMI [47] vs. REPAIR-AMI [48] ) may be the result of subtle di erences in cell handling and preparation, as di erences in BMC subpopulation pro les could result from di erent technique. Other discrepancies in these trials were evident: methods, endpoints, imaging tools evaluating cardiac function (MRI, echocardiography or angiography), patient selection, time from onset of AMI to percutaneous intervention, time from intervention to cell delivery: all these aspects may interfere with the observed responses.
The intellectual property associated with cell-based therapies is distinctly di erent from that associated with standard pharmaceutical development. This can contribute to the lack of major commercial investment into clinical development programmes. This has left physician researchers as the driving force for development, which encumbers them with greater responsibilities and investigative challenges. Individual researchers are traditionally competitive and tend to conduct multiple small studies rather than larger more informative ones. Moreover, the lack o unding for infrastructure and organization for multicentre trials could be a major barrier.
Conclusion
It comes immediately evident several weaknesses of what is known and what we are expecting from future investigations. Still few randomized controlled studies have been published, with di erent cell types and preparations, each in a small number of patients (few hundreds of patients) with di erent disease states, with short follow-up (from three till 18 months, but 6 months on averaged). So although the issue on safety is generally considered ruled out, with such few numbers we still need a ward of caution, especially if we wish to be reassured about the risk of tumour formation which may take several years before it can be excluded.
Open concerns are evident also in terms of ef cacy and clinical meaning. Preliminary results of human clinical trials have shown a modest improvement in the cardiac function of patients with acute myocardial ischaemia and infarct [85] . When transplantation was applied to patients with chronic myocardial disease or damage secondary to myocardial infarction the results were less de nitive. However, no data are still available on crucial endpoints such as increased survival or reduced hospitalization from patients treated with cardiac regeneration. Few studies have demonstrated reduction in LV volume suggesting the lack of evident antiremodelling e ect this intervention. Also the not ominously presented increases in LVEF are mostly in the range of the variability of the methodology used to assess it (imaging technique) raising some concerns regarding the real importance and clinical impact.
On the other side because the paucity of successful techniques to e ectively treat heart failure, there may be mounting pressure to expedite the clinical application of cells transplant even before the mechanisms (as well as the long-term e ects) are fully understood.
We should proceed in a manner that maximizes both the information gained and the safety of patients. Patients should be treated with cells only as part of randomized, controlled trials and only after they understand that neither the ef cacy nor the long-term risks of this approach are established. Future trials should be powered to examine clinical end points and patients should be followed over the long term and for both bene cial and adverse e ects. The enrolment of patients with a poor prognosis (i.e., large infarcts, poor left ventricular function) makes sense. They have the greatest need for therapeutic approaches and thus have the most favourable risk-bene t ratio. Demonstration o ncremental bene t, as compared with conventional therapy, is easier in these populations, and subgroup analyses suggest that they are the most likely to bene t. However, we must keep in mind that the patients with too extensive myocardial damage and more advanced tissue degeneration could not be the more ideal target for this therapy because it could be less easy to get a successful homing of progenitor cells or a favourable development into functional tissues.
The enrolment of patients with heart failure who use left ventricular assist devices as a bridge to transplantation would also provide a unique opportunity to examine cellular and molecular mechanisms through analyses of cardiac tissue acquired both before cell infusion (at implantation) and after (at transplantation). Simultaneously, we must continue to support basic and translational research that can help guide clinical investigation.
In conclusion, several issues remain to be addressed in future studies. Only in large multicentre setting, with rigorous methodological criteria we will learn more about the hopes raised but not jet con rmed.
